Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410078, P. R. China; Institute of Clinical Pharmacology, Central South University; Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, P. R. China.
Engineering Research Center of Applied Technology of Pharmacogenomics, Ministry of Education, 110 Xiangya Road, Changsha 410078, P. R. China.
Int J Biol Sci. 2022 Feb 14;18(5):1844-1851. doi: 10.7150/ijbs.66881. eCollection 2022.
Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a pandemic. With the continuous evolution of the viral genome, SARS-CoV-2 has evolved many variants. B.1.617.2, also called Delta, is one of the most concerned variants. The Delta variant was first reported in India at the end of 2020 but has spread globally, by now, to 135 countries and is not stand still. Delta shared some mutations with other variants, and owned its special mutations on spike proteins, which may be responsible for its strong transmission and increasing virulence. Under these circumstances, a systematic summary of Delta is necessary. This review will focus on the Delta variant. We will describe all the characteristics of Delta (including biological features and clinical characteristics), analyze potential reasons for its strong transmission, and provide potential protective ways for combating Delta.
新型冠状病毒病 2019（COVID-19）由严重急性呼吸系统综合征冠状病毒 2（SARS-CoV-2）引起，已成为大流行。随着病毒基因组的不断进化，SARS-CoV-2 已经进化出许多变体。B.1.617.2，也称为 Delta，是最受关注的变体之一。Delta 变体于 2020 年底在印度首次报告，但已在全球传播，现已传播到 135 个国家，且仍在不断变化。Delta 与其他变体共享一些突变，并在刺突蛋白上拥有其特殊突变，这可能是其具有强大传播性和增加毒性的原因。在这种情况下，有必要对 Delta 进行系统总结。本综述将重点介绍 Delta 变体。我们将描述 Delta 的所有特征（包括生物学特征和临床特征），分析其强大传播的潜在原因，并提供对抗 Delta 的潜在保护方法。
